Six of seven. And the FDA's own scientists voted no.

The votes

Every one of the seven votes was close. The committee had 15 voting seats.

Tallies read yes-no-abstain. The committee has not published a separate tally for MOTS-c; the other three peptides heard on July 23 each split 8-6-1. DSIP, listed on the docket under its formal name emideltide, was the single rejection and the only time in two days that the panel sided with the FDA's reviewers.

What the FDA's own scientists argued

This is the part that makes the meeting unusual. Career reviewers at the agency applied the standard four-factor test used for every bulk substance: physical and chemical characterization, history of use in compounding, evidence of effectiveness, and safety. They recommended against all seven.

On characterization, FDA official Russell Wesdyk put the problem plainly: “You will see many many different forms. We can't create quality standards until we actually know what it is.” That is a manufacturing objection more than a pharmacology one, and it is the hardest of the four to argue past. If two vials labeled BPC-157 contain measurably different molecules, no monograph can describe either of them.

Who voted, and why that is being questioned

Eight newly appointed panelists, most of whom have worked for or with companies that sell or promote peptides, made up the bloc that carried every yes vote. A Health and Human Services spokesperson said the appointments went through standard ethics vetting.

Their argument was access. People are already using these peptides in large numbers, the reasoning goes, and keeping them off the list does not stop that. It just routes demand to overseas suppliers where nobody verifies what is in the vial. Dr. Asare Christian summarized it as “I think it's about patient access.”

The dissent went after the reasoning itself rather than the molecules. Dr. Elizabeth Rebello described the panel as “responding to a market-induced demand rather than a decision based in solid science.” Dr. Brian Lee was blunter: “I think this endorsement can be potentially harmful.” The concern underneath both is precedent. If a substance can reach patients through compounding without the clinical trials an approved drug requires, there is less reason for anyone to run those trials.

What actually changed this week: nothing

This is the part most coverage buries, and it is the part that matters if you are a patient or a prescriber.

A PCAC vote is a recommendation to the FDA. It does not move a substance between categories, it does not create a compounding pathway, and it does not make anything legal. All seven peptides heard last week are still in Category 2 today, exactly where they were on July 22.

For anything to change, the FDA has to accept the recommendation, publish a proposed rule, run a public comment period, and issue a final rule. That sequence typically takes 12 to 24 months. Realistic timing is 2027 into 2028, assuming the agency goes along with a committee that just overruled its own scientists six times.

What to watch next

• The FDA decides whether to accept the recommendation. It is not bound by its advisory committees, though it usually follows them. Here its own reviewers argued the other way, which makes this less predictable than usual.
• A proposed rule, then a comment period. Adding a substance to the 503A bulks list takes formal notice-and-comment rulemaking. Comment periods typically run 60 to 90 days. The whole sequence usually takes 12 to 24 months.
• Five more peptides go before PCAC by February 2027. Cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor. A public comment docket for that meeting has not posted yet.
• Watch for a faster path. HHS Secretary Kennedy has publicly backed wider peptide access. Enforcement discretion or an interim Category 1 designation could bridge the gap before rulemaking finishes. Neither has been announced.

One quieter detail worth flagging. Ibutamoren (MK-677) was named on the April 2026 withdrawal list of 12, but it was not heard in July and does not appear on the February 2027 agenda. Pegylated mechano growth factor took the twelfth slot instead. Ibutamoren is a non-peptide small molecule, which may explain the split, but the FDA has not published a reason. For now it sits in Category 2 with no scheduled review.

Sources

• FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
• RAPS: FDA advisory committee backs two more peptides, rejects one for compounding list
• NPR: FDA advisers vote to ease peptide restrictions, despite agency concerns
• NBC News: FDA panel, with ties to the peptide industry, recommends easing restrictions
• TIME: An FDA Committee Just Voted in Favor of Peptides, Despite the Agency's Opposition
• STAT: FDA advisory panel narrowly rejects compounding of one peptide, backs two others
• Orrick: FDA Peptide Compounding Vote, What to Watch at the July PCAC Meeting

This article is editorial information, not medical or legal advice. Talk to a licensed prescriber about your treatment and a healthcare attorney about your practice.